Table 2 Treatment characteristics of the study population (n = 52).

Nab-paclitaxel discontinuation:

 • Yes

50 (96.2)

 • No

2 (3.8)

Reason for Nab-paclitaxel discontinuation:

 • Toxicity

7 (14.0)

 • Disease progression

33 (66.0)

 • Physician decision

8 (16.0)

 • Patient decision

2 (4.0)

Atezolizumab discontinuation:

 • Yes

45 (86.5)

 • No

7 (13.5)

Reason for atezolizumab discontinuation:

 • Toxicity

6 (13.3)

 • Disease progression

36 (80.0)

 • Physician decision

1 (2.2)

 • Patient decision

2 (4.4)

Atezolizumab maintenance:

 • Yes

8 (15.4)

 • No

44 (84.6)